PARP抑制剂在小细胞肺癌的研究进展  

Highlights of PAPR Inhibitors in Small Cell Lung Cancer

作　　者：张爽[1] 柳菁菁[1] 杨长良 张良[1] 李双 暴昊(综述) 程颖(审校)[1] Shuang ZHANG;Jingjing LIU;Changliang YANG;Liang ZHANG;Shuang LI;Hao BAO;Ying CHENG(Department of Vwracic Oncology,Jilin Provincial Cancer Hospital,Changchun 130012,China)

机构地区：[1]吉林省肿瘤医院胸部肿瘤内科,长春130012

出　　处：《中国肺癌杂志》2020年第9期806-810,共5页Chinese Journal of Lung Cancer

摘　　要：以早期转移,容易复发耐药,预后差为特征的小细胞肺癌(small cell lung cancer, SCLC)的治疗依然面临困境。在免疫治疗为SCLC带来新的选择后,研究者也热切的希望SCLC能够在靶向治疗领域实现突破。SCLC基因组不稳定性和对细胞毒性化疗的敏感性,使得靶向脱氧核糖核酸(deoxyribonucleic acid, DNA)修复相关途径的药物聚腺苷二磷酸核糖多聚酶(poly ADP-ribose polymerase, PARP)抑制剂成为SCLC靶向治疗研究的热点。目前PARP抑制剂在SCLC的研究既有单药治疗,也有联合其他药物的治疗策略,既包括复发SCLC的治疗和SCLC的一线诱导治疗,也包括诱导治疗后的维持治疗,这些研究也分别进行了的疗效预测标志物的探索,尽管目前PARP抑制剂在SCLC的研究结果有限,发现的疗效预测标志物也不一致,但我们也看到PARP抑制剂可能是SCLC精准治疗的突破口。Small cell lung cancer(SCLC),characterized by early metastasis,relapse,relapse and resistance and poor prognosis,still faces difficulties in treatment.Recently,Immunotherapy is a novel treatment for SCLC,researchers are also eager to achieve a breakthrough in targeted treatment of SCLC.Genomic instability of SCLC and sensitivity to cytotoxic chemotherapy,therefore,poly ADP-ribose polymerase(PARP)inhibitors targeting DNA repair related pathways have become a hotspot in the research of SCLC targeted therapy.Studies on PARP inhibitors in SCLC have been conducted in combination with other therapeutic strategies,including the treatment of recurrent SCLC and first-line treatment,as well as maintenance treatment after induction.These studies also explored the predictive markers of PARP inhibitors in SCLC.Although the current results of PARP inhibitors in SCLC are limited,and the predictive markers are also inconsistent,we also see that PARP inhibitors could be a breakthroughfor precision medicine of SCLC.

关 键 词：肺肿瘤 聚腺苷二磷酸核糖多聚酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]